ClinicalTrials.Veeva

Menu
G

Ghent University Hospital | General and Hepatobiliary Surgery

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lenalidomide
Bevacizumab
PLN-74809
Tal-DR
Nintedanib
Ustekinumab
Psilocybin
Secukinumab
Ribavirin
Elotuzumab

Parent organization

This site is a part of Ghent University Hospital

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 46 total trials

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)

This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rit...

Active, not recruiting
Marginal Zone Lymphoma
Follicular Lymphoma
Drug: tafasitamab
Drug: placebo

The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) w...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Elotuzumab
Drug: Bortezomib

The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severe...

Active, not recruiting
Colitis, Ulcerative
Drug: Placebo
Drug: JNJ-77242113

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in comb...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Talquetamab

Objectives: The aim of this study is to evaluate the effectiveness of 3M™ Cavilon™ Advanced Skin Protectant in the treatment of partial-thickness wou...

Not yet enrolling
Wound of Skin
Stoma Site Dermatitis
Device: 3M Cavilon Advanced Skin Protectant
Device: Standard hospital wound treatment protocol

A clinical trial of AAV5-hRKp.RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)

Active, not recruiting
X-Linked Retinitis Pigmentosa
Biological: Genetic: AAV5-hRKp.RPGR Intermediate Dose
Biological: Genetic: AAV5-hRKp.RPGR Low Dose

The purpose of this study is to determine the safety and feasibility of performing psilocybin-assisted psychotherapy in patients hospitalized for tre...

Enrolling
Treatment Resistant Depression
Drug: Psilocybin

This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial...

Active, not recruiting
Endometrial Cancer
Drug: INCAGN02385
Drug: pemigatinib

This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are R...

Enrolling
Myelodysplastic Syndromes
Drug: Placebo
Drug: Tamibarotene

Trial sponsors

G
Janssen (J&J Innovative Medicine) logo
Incyte logo
Allergan logo
Fresenius Kabi logo
F
H
Medtronic logo
Pfizer logo
P

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems